2,749 Becton, Dickinson and Company $BDX Shares Acquired by Kintegral Advisory LLC

Kintegral Advisory LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 46.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,684 shares of the medical instruments supplier’s stock after acquiring an additional 2,749 shares during the period. Kintegral Advisory LLC’s holdings in Becton, Dickinson and Company were worth $1,554,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $3,721,533,000. State Street Corp raised its stake in shares of Becton, Dickinson and Company by 8.5% in the second quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock valued at $2,269,960,000 after purchasing an additional 1,177,256 shares in the last quarter. First Eagle Investment Management LLC lifted its position in Becton, Dickinson and Company by 15.8% in the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares during the period. Auto Owners Insurance Co lifted its position in Becton, Dickinson and Company by 22,225.2% in the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after purchasing an additional 40,528,680 shares during the period. Finally, Bank of America Corp DE acquired a new stake in Becton, Dickinson and Company during the second quarter worth $474,993,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. This trade represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 6,906 shares of company stock valued at $1,265,855. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX traded down $2.42 during mid-day trading on Friday, reaching $191.34. The company had a trading volume of 1,412,670 shares, compared to its average volume of 1,816,545. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The company has a market capitalization of $52.72 billion, a P/E ratio of 57.63, a P/E/G ratio of 13.06 and a beta of 0.21. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $195.99. The company’s 50-day moving average is $184.03 and its 200-day moving average is $163.70.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the firm earned $3.68 EPS. Becton, Dickinson and Company’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were paid a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on BDX shares. Weiss Ratings raised shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 28th. Jefferies Financial Group restated a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective for the company. Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Finally, Bank of America upped their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, August 31st. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.